NZV930X
Total Payments
$524,741
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $298,011 | 2 | 0 |
| 2019 | $169,922 | 2 | 0 |
| 2018 | $56,807 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $524,741 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I IB OPEN LABEL MULTI CENTER DOSE ESCALATION AND DOSE EXPANSION STUDY OF THE SAFETY AND TOLLERABILITY OF NZV930 SINGLE AGENT AND IN COMBINATION WITH PDR001 AND OR NIR178 IN PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $524,741 | 0 |
Top Doctors Receiving Payments for NZV930X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $524,741 | 6 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $524,741
Product Information
- Type Drug
- Total Payments $524,741
- Total Doctors 0
- Transactions 6
About NZV930X
NZV930X is a drug associated with $524,741 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2020. In 2020, $298,011 was paid across 2 transactions to 0 doctors.
The most common payment nature for NZV930X is "Unspecified" ($524,741, 100.0% of total).
NZV930X is associated with 1 research study, including "A PHASE I IB OPEN LABEL MULTI CENTER DOSE ESCALATION AND DOSE EXPANSION STUDY OF THE SAFETY AND TOLLERABILITY OF NZV930 SINGLE AGENT AND IN COMBINATION WITH PDR001 AND OR NIR178 IN PATIENTS WITH ADVANCED MALIGNANCIES" ($524,741).